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METHODS: Two-year of data on prescribed anti-diabetic medications were also
available for the analyses. Data from this cohort were compared to an age and
gender control group of Aboriginal individuals without diabetes. Regression anal-
yses were conducted to evaluate the impact of anti-diabetic medications on glyce-
mic levels and control after covariate adjustment (e.g. age, gender, baseline HbA1c).
RESULTS: A total of 323 individuals newly diagnosed with diabetes in 2002 were
identified. The mean HbA1c levels increased from 6.8% at time of diagnosis to 8.2%
at the end of the study in 2008. A similar trend was seen for fasting glucose levels.
After adjusting for covariate, the results of the regression analyses indicated that
continuous (versus no use) and intermittent (versus no use) use of anti-diabetic
drugs have no significant impact on 2-year HbA1c levels. Other clinical results
indicated that a large proportion of the Aboriginal people had uncontrolled hyper-
tension and hyperlipidemia. The average number of visits to physician, number of
hospitalization and the length of staying at hospital were higher among the Ab-
original people with diabetes compared to their control group. CONCLUSIONS:
Consistent with previous studies, these findings suggest that a minority of Aborig-
inal people in Southwestern-Ontario achieved optimal glycemic control.
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OBJECTIVES: Hypertension and obesity are associated with long-term complica-
tions of type 2 diabetes mellitus (T2DM). A systematic literature review assessed
the comorbidities’ prevalence in adults with T2DM. METHODS: Electronic data-
bases (PubMed, Embase, and Cochrane Library) were searched for articles pub-
lished in English between 2001 and 2012 and related to T2DM plus hypertension
and/or obesity. Bibliographies of included studies were also examined. Data were
analyzed by continental regions (Africa, Asia, Europe, North America, Oceania, and
South America). RESULTS: We reviewed 2,688 abstracts and identified 92 relevant
observational studies. Hypertension was defined by varying blood pressure cut-
points (e.g., 140/90, 130/85, or 130/80 mmHg) or sometimes not clearly defined. The
prevalence rates for hypertension were: Africa, 38.5%-80%; Asia, 13.6%-85.8%; Eu-
rope, 29.3%-95%; North America, 52%-70.9%; Oceania, 79%-85%; South America,
50%-90.0%; and multiregional (Europe and Africa), 75.8%. Cutpoints for defining
obesity by body mass index (BMI) or waist circumference (WC) also varied among
the studies. The prevalence rates of obesity among adults with T2DM, were: Africa,
11.9%-54.6%; Asia, 20.1%-83.45%; Europe, 22.1%-96.9%; North America, 38%-62.4%;
Oceania, 46%-51%; South America, 30.5%-80.6%. In Europe, the combined preva-
lence of obesity defined by BMI or waist-to-hip ratio was 50.9%-98.6%. Limited data
suggest common comorbidity of both hypertension and obesity in adults with
T2DM. CONCLUSIONS: Across the globe, hypertension and obesity, separately or
together, are common comorbidities in adults with T2DM. Accurately quantifying
their prevalence in regional populations will help prioritize health care efforts for
managing these comorbidities, with a goal of reducing their long-term health and
cost consequences.
PDB16
GEOGRAPHIC VARIATION TRENDS IN DIABETES MELLITUS PREVALENCE IN THE
UNITED STATES VETERAN POPULATION
Xie L1, Wang L2, Huang A2, Li L2, Fritschel EK2, Baser O3
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Dallas, TX, USA,
3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: According to the U.S. Department of Veterans Affairs (VA), roughly
25% of veterans have been diagnosed with diabetes, and the mortality rate aver-
ages 5% per year compared to 2.6% in patients without diabetes. The goal of this
study was to examine the geographic variation in the annual prevalence of diabe-
tes mellitus (DM) in the U.S. veteran population. METHODS: The study sample was
extracted from the Veterans Health Administration (VHA) Medical SAS datasets
from 2006 through 2011. All patients diagnosed with DM throughout the study
period were identified using International Classification of Diseases 9th Revision
Clinical Modification (ICD-9-CM) diagnosis codes 250.xx, 357.2x, 362.0x and 366.41.
The change in prevalence over the 6-year period was assessed and the variation in
DM prevalence was tested by U.S. state. Statistical analyses were performed using
SAS v9.3 software.RESULTS: Puerto Rico had the highest regional prevalence of DM
with an increase from 23.79% in 2006 to 26.33% in 2011, while the western region
maintained the lowest prevalence throughout the study period (11.34% to 12.85%).
The trend in annual state-wide DM prevalence followed an increasing pattern,
particularly among southeastern states and Puerto Rico. From 2006 to 2011, the
number of states in the DM prevalence range of 15%-20% increased from 6 in 2006
(West Virginia, Nevada, Indiana, Missouri, Rhode Island, Oklahoma) to 25 states in
2011. Alaska and Hawaii were the only states to maintain prevalence below 10% in
the 6-year study.CONCLUSIONS:The uneven distribution of DM toward southeast-
ern states suggests a geographic variation in risk areas that may be useful for future
targeted intervention strategies.
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OBJECTIVES: To investigate whether nutritional, life-style or behavioural interven-
tions during pregnancy or early life alter risk factors of developing metabolic syn-
drome and diabetes mellitus and to gain knowledge about the burden of the dis-
ease in population of Bangladesh, India and Pakistan. METHODS: A systematic
search, using controlled and free terms (i.e.- metabolic-syndrome, glucose-intoler-
ance, diabetes-mellitus, pregnancy, fetal development, life-style, nutrition) was
conducted in Medline, Centre for Reviews and Dissemination and Cochrane Library
databases. It was completed by pearling and hand-searching. Two reviewers as-
sessed independently the results retrieved in the search, to adopt a decision on
inclusion/exclusion. The quality of included papers was appraised with STROBE
checklist for observational studies and Centre for Evidence Based Medicine check-
lists for any other study design. The present review is part of the GIFTS project
funded by Seventh Framework Programme of European Commission. RESULTS:
The search strategy identified a total of 3,278 papers. After exclusion by title, ab-
stract or duplicated 424 full text articles were retrieved. Up to now we have as-
sessed the 138 latest published papers, excluding 37. Of the 101 included articles 8
were randomized controlled trials, mainly focused on improving maternal and
fetal outcomes with nutritional supplementation, but also with community-based
interventions. There were another 47 observational studies, including long term
follow-up cohorts, which established relationship between fetal development and
posterior increased risk of metabolic syndrome for mothers and offspring. The
other ones are reviews, most of them narrative reviews, heightening the burden of
disease in these countries, the relevance of the pregnancy period, and the necessity
of implement preventing strategies. CONCLUSIONS: Metabolic syndrome is a
health problem of great magnitude in Bangladesh, India and Pakistan. As early life
determinants of the disease are clearly stated, it would be important to now design
feasible and cost-effective interventions to prevent disease.
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OBJECTIVES: To determine the population attributable risk (PAR) of microvascular
events associated with HbA1c, systolic blood pressure (SBP), or body mass index
(BMI)in patients with type 2 diabetes mellitus (T2DM). METHODS: From the
PHARMO database 6010 T2DM patients were followed in the period 2000-2008 after
at least 6 months of antidiabetic treatment (median 25, iqr 9-51 months). Survival
models based on regularly monitored risk factors, other characteristics and regis-
tered complications were used to estimate the expected number of complications
(renal failure, retinopathy, ulcers / amputations) after 5 years (base-case). The
estimated number of averted cases after reducing risk factors divided by the base-
case number resulted in the PAR. RESULTS: Mean age was 66 years (SD 12), 55%
were men. 45% had elevated HbA1c (7.0%), averaging 7.8% (SD 0.8). HbA1c reduc-
tions of 0.5% or to target (7.0%) led to significant case reductions of renal failure of
3% and 5% and of retinopathy by 6% and 10%, respectively. 66% had elevated SBP
(140 mmHg), averaging 161 mmHg (sd 16). SBP was not significantly associated
with microvascular complications. 85% had elevated BMI (25.0 kg/m2) averaging
30.7 kg/m2 (SD 4.5). BMI reductions of 10% (mean 8.7 kg) or to target (25.0 kg/m2,
mean 15.8 kg) led to significant case reductions of ulcers of 20% and 35%, but an
increase of retinopathy of 7% and 12%, respectively.Eliminating all risk factors in
the model would have averted 99 out of 493 renal failure cases (PAR 20%), 148 out of
566 ulcer cases (PAR 26%) and 21 out of 580 retinopathy cases (PAR 4%) after 5 years.
Reductions of 0.5% HbA1c, 10 mmHg SBP and 10% BMI would have averted 11% of
renal failure, 16% of ulcers and 1% of retinopathy. CONCLUSIONS: Even modest
changes in HbA1c and BMI led to significant reductions in microvascular compli-
cations.
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OBJECTIVES: To identify recent data describing the long-term risk of complications
in patients with type 1 diabetes mellitus (T1DM), and their association with glyco-
sylated haemoglobin (HbA1c) and other risk factors, and to select complications
and related data for inclusion in a new cost-utility model for T1DM. METHODS: A
systematic review was performed. The following electronic databases were
searched (1 January 2003-27 July 2011): MEDLINE, MEDLINE In-Process, EMBASE,
and the Cochrane Library, including the Health Technology Assessment (HTA)
database. Relevant clinical guidelines and HTA documentation were also searched.
RESULTS: A total of 4,846 titles were screened; 281 reports of 72 unique studies
were included for qualitative synthesis. Multiple reports were identified for several
studies, including the Diabetes Control and Complications Trial and the Epidemi-
ology of Diabetes Interventions and Complications follow-up study (DCCT/EDIC),
the Epidemiology of Diabetes Complications (EDC) study, the Finnish Diabetic Ne-
phropathy (FinnDiane) Study, the Wisconsin Epidemiologic Study of Diabetic Ret-
inopathy, the EURODIAB type 1 complications study, and several other large obser-
vational and registry studies. Data were extracted for 57 T1DM complications in
adults and 20 in children and adolescents. Complications were selected for inclu-
sion in the cost-utility model where there was evidence for a statistical association
with T1DM and HbA1c levels, an impact on mortality, and an expected impact on
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costs and/or health-related quality of life. The following complications were se-
lected: cardiovascular disease, peripheral neuropathy, renal disease, retinopathy,
cataract, hypoglycemia, ketoacidosis and adverse birth outcomes. CONCLUSIONS:
Since 2003, 281 reports of 72 studies (including many large, observational studies)
have been published. These reports have substantially increased the available ev-
idence describing complications in T1DM patients. The DCCT/EDIC studies
uniquely provide long-term follow-up (now more than 23 years) of patients man-
aged using strategies that are reasonably representative of contemporary T1DM
management.
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OBJECTIVES: To evaluate the safety of preoperative vitamin D replacement in mild
primary hyperparathyroidism. METHODS: Data were searched from Medline, EM-
BASE, Cochrane CENTRAL and abstracts form annual scientific meetings of various
international bone and mineral societies. Studies examining the effect of preoper-
ative vitamin D replacement in patients with mild primary hyperparathyroidism
(serum calcium 12 mg/dl), irrespective of year and language of the publication
were included in the present meta-analysis. Data were extracted from text of the
included publications or abstract of conferences. RESULTS: The pooled mean dif-
ference for serum calcium, phosphate, intact parathyroid hormone levels and uri-
nary calcium excretion before and after vitamin D replacement in mild primary
hyperparathyroidism were 0.06 mg/dl (95% CI, -0.11, 0.23, Z  0.71, P  0.48), -0.01
mg/dl (95% CI, -0.14, 0.13, Z  0.12, P  0.91), 17.18 pg/ml (95% CI, 1.26, 33.11, Z 
2.11, P  0.03), -56.95 mg/24hr (-104.28, -9.62, Z  2.36, P  0.02) ) respectively.
CONCLUSIONS: Preoperative vitamin D replacement in subjects with mild primary
hyperparathyroidism and vitamin D deficiency is safe. This meta-analysis sup-
ports the recommendation on replacement of vitamin D in subjects with primary
hyperparathyroidism and vitamin D deficiency by Third international workshop on
diagnosis of asymptomatic primary hyperparathyroidism.
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OBJECTIVES: Pasireotide is a novel, injectable multireceptor-targeted somatostatin
analogue that binds with high affinity to four of the five somatostatin receptors. It
has been commercially available in Europe since May 2012 and is the first pituitary-
targeted medical therapy indicated for adult patients with Cushing’s disease (CD)
for whom surgery has failed or is not an option. This analysis aims to quantify the
budget impact (BI) of utilizing pasireotide as second-line therapy in CD in Germany.
METHODS: A thorough chart audit was conducted to analyze resource utilization
and market shares of standard of care in CD. Epidemiology, treatment response
complications and adverse event (AE) data were derived from published literature.
Pasireotide data were taken from a Phase III clinical trial. German tariffs for each
resource were then applied to an Excel-based model to compare utilization and
costs with and without the introduction of pasireotide (net BI) for patients with CD
over a 5-year horizon from the German health care system. RESULTS: Applying a
CD prevalence rate of 39 per million and the treatment success of first-line therapy,
fewer than 200 patients with CD are eligible for pasireotide treatment in Germany.
Assuming that pasireotide in years 1–5 will have a market share of 8%, 15%, 23%,
25% and 26%, the net BI is 812,769€, 549,676€, 1,553,976€, 2,088,511€ and 2,209,948€,
respectively. Budget impact is reduced by early identification of pasireotide non-
responders, low cost of treating pasireotide AEs, and potential displacement of
second-line surgical treatments such as bilateral adrenalectomy. Pasireotide BI
may be further minimized if offsets due to lower consumption of health care re-
sources in controlled patients are considered. CONCLUSIONS: The introduction of
pasireotide into the German health care system will result in clinical benefits for
CD patients associated with a limited and predictable BI.
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OBJECTIVES: Linagliptin is a new oral hypoglycaemiant agent (OHA) from the class
of dipeptidyl peptidase 4 (DPP-4) inhibitors, mostly excreted by biliary pathway,
that has no contra-indication in renal impaired patients. Linagliptin in indicated
for dual therapy (add on to metformin) and for triple therapy (add on to metformin
and Sulfamides).”. The aim of this study is to estimate the potential budget impact
of linagliptin (either as mono substance or in combination with metformin) from
most current DPP-4 inhibitor prescribing patterns. METHODS: A budget impact
model was developed from a French payer perspective. The model focused on
drugs and insulin administration costs. Three prescription patterns were consid-
ered for linagliptin treatment initiation: substitution without treatment intensifi-
cation, substitution with treatment intensification and initiation in naïve patients.
Treatment initiation data were obtained via retrospective analysis of 2011 prescrib-
ing data from the Thales database. DPP-4 inhibitors latest entrants (saxagliptin/
vildagliptin-metformin combinations) were used as benchmark for linagliptin. For
analysis purpose, the daily cost of linagliptin was assumed at market average
(1.19€/day exfactory). RESULTS: Considering a virtual cohort of 10,000 patients
treated with linagliptin (mono or combination with metformin), the whole treat-
ment cost over 5 years would be 21,717 k€ compared with 18,996 k€ for a cohort of
the same size treated with current alternatives. Benefits were observed among
patients receiving triple therapy mainly because of competition with substitution
of more expensive drugs such as GLP1 analogues and insulins. Sensitivity analysis
showed that deploying the “add on to insulin indication” could reduce the budget
impact up to 8 %. CONCLUSIONS: The estimated budget impact of linagliptin will
be close to neutrality, as around 87.5 % of linagliptin costs are already offset by
substitutions, based on conservative assumptions.
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OBJECTIVES: To measure the economic impact of insulin analogues, and its partial
substitution by human insulin on the Mexican Institute of Social Security (IMSS)
health expenditure METHODS: Considering similar efficacy in both types of insu-
lin, a retrospective analysis on the supply department of the Administrative Direc-
torate database, at the IMSS, was conducted. The consumed volume during 2011
was identified; all types of insulin included in the IMSS formulary were incorpo-
rated to the analysis. The information gathered was stratified by analogue and
human insulin. The share in volume and monetary values was established for all
insulin at the institutional market. The information was traspolated to 2012 prices.
The impact on the expenditure was analyzed when analogue insulin was substi-
tuted by human insulin in 25 and 50%. Potential savings for the IMSS were obtained
if analogue insulin consumption is reduced by substituting it with human insulin.
An exchange rate of 14 MXN to 1 USD updated to May the 30, 2012 was considered
RESULTS: The IMSS total expense in insulin in 2011 reached $41,281,671.26 USD,
76.3% was expend on analogue insulin whilst it only represented 19.3% of all insu-
lin purchased in 2011. The information transpolated to 2012 prices, showed
$43,208,169.84 USD or an increase by 4.6% in expenditure considering the same
institutional insulin market share. Substituting 25% of the volume of analogue
insulin with human insulin may lead to savings in $7,971,446.06 USD equivalent to
18.4% of the expected expenditure for 2012, meanwhile substituting 50% of the
volume of analogue insulin with human insulin leads to potentials savings by
$15,942,892.11 USD, equivalent to 36.9% of the expected expenditure for 2012
CONCLUSIONS: Substituting analogue insulin by human insulin in 50% is associ-
ated to a drop in 36.9% in the total insulin expenditure at the IMSS not affecting
health outcomes in diabetic patients
PDB24
COST ANALYSIS OF ADDING PREGABALIN OR GABAPENTIN TO USUAL CARE IN
THE MANAGEMENT OF COMMUNITY-TREATED PATIENTS WITH PAINFUL
DIABETES PERIPHERAL NEUROPATHY IN SPAIN
Sicras-mainar A1, Rejas J2, Navarro-artieda R3, Planas A4, Collados C5
1Badalona Serveis Assistencials, Badalona, Barcelona, Spain, 2Pfizer España, Alcobendas/Madrid,
Spain, 3Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, 4Hospital
Municipal de Badalona, Badalona, Barcelona, Spain, 5Pfizer Spain, Alcobendas (Madrid), Spain
OBJECTIVES: To compare health care resources utilization and corresponding
costs in adults patients with painful Diabetes Peripheral Neuropathy (pDPN) who
initiated treatment with pregabalin or gabapentin as an add-on therapy to usual
care in Spanish daily medical practice setting.METHODS:A retrospective database
study was designed including systematically all medical records of adult patients,
with pDPN (ICD-9-CM codes; 250.6-357.2), both gender, who were covered by the
BSA health plan in years 2006-2009, and that initiated treatment with pregabalin or
gabapentin as an add-on therapy for the first time. Socio-demographics, co-mor-
bidity burden index, treatment duration, all type health care resources and days
off-work due to pDPN were assessed. Societal perspective was applied in estimat-
ing costs. Comparisons of costs were adjusted by age, sex and the Charlson index of
co-morbidity. RESULTS: A total of 395 medical records were eligible for analysis:
227 (57.5%) with pregabalin and 168 (42.5%) with gabapentin. No significant differ-
ences were observed in previous exposition to analgesics: pregabalin 2.7 (1.9) drugs;
gabapentin 2.6 (1.9), p0.05. However, concomitant use of analgesics was higher in
gabapentin cohort; 3.9 (2.2) vs. 3.1 (2.1); p0.05, mainly due to a higher utilization of
non-narcotics (78.0% vs. 71.8%; p0.05) and opioids (32.7% vs. 28.6%; p0.05).
Health care costs accounted for the 59.2% of total cost, with a mean cost per patient
of €2,476. Adjusted mean (95% CI) total costs were significantly lower in patients
receiving pregabalin [€2,003 (1,427-2,579)] compared with those treated with gaba-
pentin [€3,127 (2,463-3,790)], p0.013, mainly due to lower health care costs; €1,312
(1,192-1,432) versus €1,675 (1,537-1,814), respectively (p0.001). Less use of con-
comitant analgesics, medical visits and days off-work accounted for such findings.
CONCLUSIONS: Treatment of pDPN patients with pregabalin add-on to usual care
could be a cost-saving alternative from the societal perspective when compared
with gabapentin in real world settings in Spain.
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